Neurophysiological and biomolecular effects of erenumab in chronic migraine: An open label study - Roberto De Icco, Giuseppe Fiamingo, Rosaria Greco, Sara Bottiroli, Chiara Demartini, Anna Maria Zanaboni, Marta Allena, Elena Guaschino,
A systematic review, meta-analysis and meta-regression evaluating the adverse reactions to erenumab in the preventive treatment of migraine: Expert Opinion on Drug Safety: Vol 20, No 4
PDF) Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial
Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial | The Journal of Headache and Pain | Full Text
Erenumab Tied to Rapid Conversion From Chronic to Acute Migraine
Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial | The Journal of Headache and Pain | Full Text
Migraine: integrated approaches to clinical management and emerging treatments - The Lancet
Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial | The Journal of Headache and Pain | Full Text
The International Headache Congress – IHS and EHF joint congress 2021: late breaking abstracts | The Journal of Headache and Pain | Full Text
PDF) Erenumab Efficacy on Comorbid Cluster Headache in Patients With Migraine: A Real‐World Case Series
PDF) Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial
63rd Annual Scientific Meeting American Headache Society® - 2021 - Headache: The Journal of Head and Face Pain - Wiley Online Library
Post-traumatic headache attributed to traumatic brain injury: classification, clinical characteristics, and treatment - The Lancet Neurology
MONOCLONAL ANTIBODIES TARGETING CGRP: FOR WHOM AND FOR HOW LONG'
Getting closer to a cure for migraine | Nature Reviews Neurology
MONOCLONAL ANTIBODIES TARGETING CGRP: FOR WHOM AND FOR HOW LONG'
PDF) Psychological Predictors of Negative Treatment Outcome with Erenumab in Chronic Migraine: Data From an Open Label Long-Term Prospective Study
MONOCLONAL ANTIBODIES TARGETING CGRP: FOR WHOM AND FOR HOW LONG'
Daniele MARTINELLI | PhD Student | Doctor of Medicine | University of Pavia, Pavia | UNIPV | Department of Brain and Behavioral Sciences | Research profile
63rd Annual Scientific Meeting American Headache Society® - 2021 - Headache: The Journal of Head and Face Pain - Wiley Online Library
Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE
Correction to: Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label
Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial | The Journal of Headache and Pain | Full Text
Does erenumab suspension affect chronic migraine course? A real life experience
MONOCLONAL ANTIBODIES TARGETING CGRP: FOR WHOM AND FOR HOW LONG'
PDF) A systematic review, meta-analysis and meta-regression evaluating the adverse reactions to erenumab in the preventive treatment of migraine
Neurophysiological and biomolecular effects of erenumab in chronic migraine: An open label study - Roberto De Icco, Giuseppe Fiamingo, Rosaria Greco, Sara Bottiroli, Chiara Demartini, Anna Maria Zanaboni, Marta Allena, Elena Guaschino,
